| scholarly article | Q13442814 |
| P2093 | author name string | Mark Goodfield | |
| Naila Usmani | |||
| P433 | issue | 7 | |
| P304 | page(s) | 873-877 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Archives of Dermatology | Q15749524 |
| P1476 | title | Efalizumab in the treatment of discoid lupus erythematosus. | |
| P478 | volume | 143 |
| Q42141973 | Biological therapy in systemic lupus erythematosus |
| Q33607620 | Biologics in dermatologic therapy - an update |
| Q37778643 | Cutaneous lupus erythematosus: recent lessons from animal models |
| Q36134951 | Cutaneous manifestations of systemic lupus erythematosus. |
| Q24240456 | Drugs for discoid lupus erythematosus |
| Q30234556 | Drugs for discoid lupus erythematosus. |
| Q37000358 | Emerging biological therapies in systemic lupus erythematosus |
| Q38135706 | Future prospects in biologic therapy for systemic lupus erythematosus |
| Q37401088 | Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives |
| Q37167668 | Management of primary cicatricial alopecias: options for treatment. |
| Q41938484 | Successful therapy of discoid lupus erythematosus with efalizumab |
| Q38191835 | Systemic lupus erythematosus: a therapeutic challenge for the XXI century |
| Q34075552 | T cells as therapeutic targets in SLE. |
| Q84697085 | Treatment of cutaneous lupus erythematosus |
| Q80516806 | [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] |
| Q84582111 | [Refractory subacute cutaneous lupus erythematosus with a response to efalizumab] |
| Q46024345 | [Two faces of Janus. Coexistence of systemic lupus erythematosus and psoriasis in the same patient]. |
Search more.